Cybin (NYSEAMERICAN:CYBN) Shares Down 4.4%

Cybin Inc. (NYSEAMERICAN:CYBN) shares were down 4.4% on Thursday . The stock traded as low as $9.85 and last traded at $9.88. Approximately 70,485 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 140,300 shares. The stock had previously closed at $10.34.

Cybin Stock Performance

The stock has a market capitalization of $4.05 billion, a P/E ratio of -45.48 and a beta of 0.50.

Cybin (NYSEAMERICAN:CYBN) last posted its earnings results on Thursday, August 8th. The company reported ($0.01) EPS for the quarter. On average, equities analysts anticipate that Cybin Inc. will post -0.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cybin stock. Rathbones Group PLC bought a new stake in Cybin Inc. (NYSEAMERICAN:CYBN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 65,381 shares of the company’s stock, valued at approximately $26,000. Institutional investors and hedge funds own 17.94% of the company’s stock.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.